$616 Million is the total value of GREAT POINT PARTNERS LLC's 33 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 466.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RCKT | New | ROCKET PHARMACEUTICALS INC | $38,388,000 | – | 700,000 | +100.0% | 6.24% | – |
| XENT | Buy | INTERSECT ENT INC | $29,836,000 | +144.6% | 1,302,871 | +74.2% | 4.85% | +341.8% |
| OCUL | New | OCULAR THERAPEUTIX INC | $17,723,000 | – | 856,162 | +100.0% | 2.88% | – |
| KDMN | Buy | KADMON HLDGS INC | $16,948,000 | +72.9% | 4,083,909 | +63.4% | 2.75% | +212.1% |
| PODD | New | INSULET CORP | $15,338,000 | – | 60,000 | +100.0% | 2.49% | – |
| TBPH | New | THERAVANCE BIOPHARMA INC | $14,653,000 | – | 824,580 | +100.0% | 2.38% | – |
| ARVN | New | ARVINAS INC | $13,941,000 | – | 164,150 | +100.0% | 2.26% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $13,338,000 | +19.9% | 1,300,000 | +18.0% | 2.17% | +116.6% |
| MRSN | New | MERSANA THERAPEUTICS INC | $12,971,000 | – | 487,452 | +100.0% | 2.11% | – |
| EXEL | New | EXELIXIS INC | $9,533,000 | – | 475,000 | +100.0% | 1.55% | – |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $8,440,000 | – | 421,383 | +100.0% | 1.37% | – |
| FMTX | New | FORMA THERAPEUTICS HLDGS INC | $8,250,000 | – | 236,400 | +100.0% | 1.34% | – |
| FGEN | New | FIBROGEN INCcall | $6,176,000 | – | 166,500 | +100.0% | 1.00% | – |
| LUNG | New | PULMONX CORP | $4,441,000 | – | 64,345 | +100.0% | 0.72% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $4,241,000 | – | 75,000 | +100.0% | 0.69% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $3,244,000 | – | 70,000 | +100.0% | 0.53% | – |
| CALA | New | CALITHERA BIOSCIENCES INCcall | $2,455,000 | – | 500,000 | +100.0% | 0.40% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.